Ex Vivo Data Presented at EHA2022 Congress
Faron Pharmaceuticals Ltd. (“Faron” or “Company”) Ex Vivo Data Presented at EHA2022 Congress Suggest Critical Role for Clever-1 in Hematological Cancer Outcome and Drug Resistance · Clever-1 is expressed in patient bone marrow blasts and monocytes in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), with the highest levels observed in M4/M5 subtypes with poor outcome · Blocking Clever-1 with bexmarilimab in these patients induced immune activation as observed through increased antigen presenting molecule, human leucocyte antigen DR (HLA-DR)